Loading...
Atovaquone — Export Intelligence Report
2025-Q4 · TransData Nexus
PHARMA TRADE INTELLIGENCE
INDIA EXPORT INTELLIGENCE REPORT
Atovaquone
2025-Q4
Comprehensive analysis of India’s atovaquone export trade — suppliers, buyers, prices, routes, and every shipment record.
55
Shipments
$6.27M
Trade Value
8
Suppliers
14
Buyers
9
Countries
Scan for online report
Talk to our analyst: +91 95950 78788
https://transdatanexus.com/pharmaceutical/atovaquone
01
PART I — OVERVIEW
Executive Summary
At-a-glance KPIs, key findings, and strategic positioning of India’s atovaquone trade — 2025-Q4
KEY TAKEAWAY
Atovaquone 2025-Q4 exports total $6.3M across 9 countries, with HETERO LABS LTD commanding 50.9% market share.
TOTAL SHIPMENTS
55
2025-Q4
EXPORT VALUE
$6.3M
FOB USD
TOTAL QUANTITY
1.3M
units shipped
INDIAN SUPPLIERS
8
unique exporters
GLOBAL BUYERS
14
unique importers
DESTINATIONS
9
countries
MEDIAN UNIT PRICE
$14.18
per unit
TOP-5 SHARE
99.9%
of total USD
BRANDED SHARE
38.2%
21 shipments
DOSAGE FORMS
3
product types
6 KEY FINDINGS
1
HETERO LABS LTD is India's #1 Atovaquone exporter with $3.2M (50.9% market share).→ §5, Indian Supplier Rankings
2
Atovaquone reached 9 countries, with United States as the top destination ($5.8M).→ §4, Global Destination Map
3
Market concentration is high (HHI: 4601) — top 8 suppliers control 100.0% of exports.→ §5, Indian Supplier Rankings
4
92.9% of buyers (13 of 14) source from a single Indian supplier — potential poaching opportunities.→ §6, Global Buyer Rankings
5
Tablet dominates (49.0%) across 3 dosage forms.→ §7, Price Benchmarks
6
9 countries have ≤5 Indian suppliers — easy-entry markets for SME exporters.→ §9, Strategic Opportunities
WHO THIS REPORT IS FOR
S SUPPLIERS (Indian pharma exporters)
- See which buyers your competitors are shipping to, at what price, through which ports
- Identify buyers that are single-sourced (poaching opportunities)
- Benchmark your pricing and catalog vs the Top 25
B BUYERS (global importers)
- Discover which Indian exporters supply this product and what they sell
- Benchmark the price you are paying vs the market median by country and dosage
- Identify alternative suppliers with proven exports to similar destinations
Figure 1.1 HETERO LABS LTD leads in volume — how do 8 exporters compare on price × volume?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Every bubble is one Indian atovaquone exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Atovaquone report covers
KEY TAKEAWAY
Every figure in this report is grounded in real commercial atovaquone trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian atovaquone suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Atovaquone India trade report
Product scope
Atovaquone
All variants merged — branded and generic formulations of atovaquone
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
Shipments analysed
55
Every commercial atovaquone trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
DATA ACCURACY
99.9%
Validation rate on core fields — supplier, buyer, product, quantity, value.
UPDATE FREQUENCY
Daily
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
- Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
- This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
- A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
- This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY
2025-Q4 followed a v-curve: Oct $3.8M, Nov $602.6K, Dec $1.9M. Shipment counts rose across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$3.8M
Oct USD
20 shipments
2
$602.6K
Nov USD
-84.2% MoM
3
$1.9M
Dec USD
+208.6% MoM
4
V-curve
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov dipped 84.2% in USD but shipment count kept steady.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $3.8M, making it the strongest month by value.
Fig 3.2 Q4 cumulative USD reached $6.3M.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
Fig 3.3 $3.2M dip in Nov, $1.3M recovery in Dec.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = absolute monthly value. Red = month-over-month loss; green = gain. Insight: Nov’s dip was fully recovered by Dec.
Fig 3.4 Regional breakdown by month — which corridors swung most?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
§3.1 Monthly summary
| Oct | $3.8M | 20 shipments |
| Nov | $603K | 5 shipments |
| Dec | $1.9M | 30 shipments |
| Q4 Total | $6.3M | 55 shipments |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 3.5 Top 9 destination countries by monthly USD rank — who’s rising?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a country’s monthly rank. Lines crossing = rank swaps. Insight: United States held #1 throughout the quarter.
Fig 3.6 Top 8 Indian exporters by monthly USD rank.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: HETERO LABS LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import atovaquone from India, how much they buy, and who supplies each market
KEY TAKEAWAY
United States absorbs 92.7% of India’s 2025-Q4 atovaquone trade ($5.8M). Beyond the top 9 destinations, 9 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Americas has 3 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 9 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much atovaquone India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$78
0.0% of trade
1 countries · 1 shipments
Europe
$275K
4.4% of trade
2 countries · 15 shipments
Americas
$5.9M
94.9% of trade
3 countries · 36 shipments
Africa
$35K
0.6% of trade
2 countries · 2 shipments
Oceania
$12K
0.2% of trade
1 countries · 1 shipments
Fig 4.1 United States is the #1 corridor ($5.8M) — 9 flow arcs from India radiate across 5 continents.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The world map shows every country colored by how much Indian atovaquone it receives (light = low, dark = high). Orange arcs radiate from India to the top 9 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 9 bilateral trade lanes (India → destination) with top Indian suppliers
| # | Destination | Total USD | Ships | #1 Indian supplier | USD | #2 Indian supplier | USD | #3 Indian supplier | USD |
|---|---|---|---|---|---|---|---|---|---|
| 1 | United States | $5.8M | 34 | HETERO LABS LTD | $3.2M | GLENMARK PHARMACEUTICALS LTD | $2.4M | MYLAN LABORATORIES LTD | $228K |
| 2 | Germany | $275K | 6 | GLENMARK PHARMACEUTICALS LTD | $275K | — | — | — | — |
| 3 | Canada | $134K | 1 | GLENMARK PHARMACEUTICALS LTD | $134K | — | — | — | — |
| 4 | Mauritius | $29K | 1 | GLENMARK PHARMACEUTICALS LTD | $29K | — | — | — | — |
| 5 | Australia | $12K | 1 | ALKEM LABORATORIES LTD | $12K | — | — | — | — |
| 6 | South Africa | $5K | 1 | HUMANIQE BIOPHARMACEUTICALS PVT LTD | $5K | — | — | — | — |
| 7 | American Samoa | $1K | 1 | VIVALDIS HEALTH AND FOODS PVT LTD | $1K | — | — | — | — |
| 8 | United Arab Emirates | $78 | 1 | MEDLINE WORLD SURGICARE PVT LTD | $78 | — | — | — | — |
| 9 | Romania | $12 | 9 | GLENMARK PHARMACEUTICALS LTD | $12 | — | — | — | — |
Table 4.1 — Top 9 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 0.0% of USD — but United States is the single largest market.
Region → country treemap
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
92.7%
#1 country share
United States alone
99.9%
Top 5 share
5 of 9 countries
100.0%
Top 15 share
Long tail of -6 countries = 0.0%
HHI 8620
Destination HHI
Highly concentrated
9
Countries served
Global pharma reach from India
3
Americas countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
8 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAY
HETERO LABS LTD ($3.2M, 50.9% share) and GLENMARK PHARMACEUTICALS LTD ($2.8M) together control 95.6% of India’s 2025-Q4 atovaquone trade. The top 5 suppliers hold 99.9%. 8 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian atovaquone suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 HETERO LABS LTD leads by $392K over GLENMARK PHARMACEUTICALS LTD — top 8 Indian exporters ranked by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: HETERO LABS LTD is #1 by value but #2 by volume.
Fig 5.2 GLENMARK PHARMACEUTICALS LTD also leads by shipment count (24) but ranking shifts for volume-heavy players
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: HETERO LABS LTD moves from #2 by volume to #1 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 8 atovaquone suppliers split into strategic segments
KEY TAKEAWAY
2 suppliers (25%) generate 95.6% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 HETERO LABS LTD and GLENMARK PHARMACEUTICALS LTD sit in the leaders zone — high volume AND high value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 95.6% of USD — classic concentration.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Top bar = supplier %, bottom bar = USD %. The gap = market concentration.
Product variety — how many formulations each supplier ships
| # | Supplier | Dosage forms | Countries | USD |
|---|---|---|---|---|
| 1 | HETERO LABS LTD | 2 | 1 | $3.2M |
| 2 | GLENMARK PHARMACEUTICALS LTD | 2 | 5 | $2.8M |
| 3 | MYLAN LABORATORIES LTD | 1 | 1 | $228K |
| 4 | PIRAMAL PHARMA LTD | 1 | 1 | $30K |
| 5 | ALKEM LABORATORIES LTD | 1 | 1 | $12K |
| 6 | HUMANIQE BIOPHARMACEUTICALS PVT LTD | 1 | 1 | $5K |
| 7 | VIVALDIS HEALTH AND FOODS PVT LTD | 1 | 1 | $1K |
| 8 | MEDLINE WORLD SURGICARE PVT LTD | 1 | 1 | $78 |
Table 5.1 — The more dosage forms a supplier ships, the more versatile their manufacturing capability.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — India Origin Geography & Concentration
Which Indian cities and states are the atovaquone manufacturing hubs
KEY TAKEAWAY
Hyderabad and Mumbai. Maharashtra together account for $5.4M of India’s 2025-Q4 atovaquone trade.
Fig 5.5 Hyderabad (1 exporters, $3.2M) and Mumbai. Maharashtra (1 exporters, $2.2M) are India’s atovaquone capitals.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Orange bubbles mark major pharma hub cities; bubble size = USD value. Every hub labeled.
§5.1 Supplier concentration metrics
99.9%
Top 5 share
5 of 8 suppliers
100.0%
Top 8 share
8 of 8 suppliers
95.6%
Top 25% share
2 suppliers = 96% USD
HHI 4601
Supplier HHI
Concentrated
8
Total suppliers
shipped Atovaquone in 2025-Q4
11+ cities
Indian hubs
Hyderabad and Mumbai. Maharashtra lead
§5.2 Coming next: 1 exporter deep-dive profiles
Each of the top 1 suppliers gets a dedicated 2-page profile with:
- 6 KPI cards — trade value, shipments, countries, buyers, avg ship value, branded share
- Dosage form breakdown — what formulations they ship
- Monthly trend — Oct / Nov / Dec trajectory
- Trade flow map — supplier → country → importer connections
- Buyer portfolio with lock-in analysis
SUPPLIER PROFILES IN THIS REPORT
| #1 | GLENMARK PHARMACEUTICALS LTD | $2.8M |
#2
EXPORTER PROFILE #1 OF 1
GLENMARK PHARMACEUTICALS LTD
Mumbai. Maharashtra · India’s #2 atovaquone supplier by USD · 2025-Q4
2025-Q4 USD
$2.8M
44.7% market share
SHIPMENTS
24
avg $117K/ship
COUNTRIES
5
destination markets
BUYERS
7
7 single-sourced
BRANDED
67%
of shipments
DOSAGE FORMS
2
product types
TOP 5 DESTINATIONS
United States is the #1 market at $2.4M (84% of trade), followed by Germany at $275K. 5 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | United States | $2.4M | 7 | 84.4% |
| 2 | Germany | $275K | 6 | 9.8% |
| 3 | Canada | $134K | 1 | 4.8% |
| 4 | Mauritius | $29K | 1 | 1.0% |
| 5 | Romania | $12 | 9 | 0.0% |
MONTHLY TREND
Oct peaked at $2.2M. Dec was the weakest at $4K.
PRODUCT MIX
Tablet dominates at 100% of trade. Suspension (0.2%) and others are secondary formulations.
TOP BUYERS · 7/7 LOCKED IN
7 of 7 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| GLENMARK PHARMACEUTICA… | United States | $2.4M | ⚠ Locked |
| CENTRAFARM SERVICES (A… | Germany | $174K | ⚠ Locked |
| GLENMARK PHARMACEUTICA… | Canada | $134K | ⚠ Locked |
| EUROGENERICS NVLIVLINA… | Germany | $97K | ⚠ Locked |
| SCOTT HEALTH LTD | Mauritius | $29K | ⚠ Locked |
| GLENMARK PHARMACEUTICA… | Germany | $4K | ⚠ Locked |
| STADA HEMOFARM SRL | Romania | $12 | ⚠ Locked |
#2
EXPORTER PROFILE #1 OF 1 — TRADE FLOW MAP
GLENMARK PHARMACEUTICALS LTD — Supplier → Country → Importer
5 destination countries, top 5 importers per country
Fig 5.P1.3 United States absorbs $2.4M — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 5 destinations and up to 3 importers per destination.
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
14 importers across 9 countries — who is buying Indian atovaquone and how much
KEY TAKEAWAY
The demand side is dramatically more fragmented than supply: the top 13 importers together hold only 50.0% of total USD. 93% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian atovaquone. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 GLENMARK PHARMACEUTICALS INC is the #1 importer at $2.4M (37.7%) — top 13 by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one global importer ranked by USD.
Fig 6.2 Re-ranked by shipment count — compare with Fig 6.1 for divergences
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same 13 importers re-ranked by shipment count.
§6.1 Sourcing diversity — how many Indian suppliers does each buyer use?
93%
Single-source
13 buyers rely on exactly 1 Indian supplier
7%
Dual-source
1 buyers use 2 Indian suppliers
0%
Multi-source (3–4)
0 buyers diversified across 3–4
0%
Broad-source (5+)
0 buyers with 5+ Indian suppliers
06
PART III — WHO’S IN THIS MARKET
Single-Source Buyers & Price Benchmark
Lock-in opportunities grouped by country + where each buyer sits on the price spectrum
KEY TAKEAWAY
These importers source atovaquone from exactly one Indian supplier. For each one, the table shows the incumbent, price, and dosage.
S FOR SUPPLIERS
This is your target list. Each row is a buyer locked into one competitor. Offer 5–10% better pricing to win the second-source slot.
B FOR BUYERS
If you see your company here, you are fully dependent on one Indian supplier. Consider qualifying a second source.
§6.2 Single-source lock-in by country
United States 4 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| GLENMARK PHARMACEUTICA… | GLENMARK PHARMACEUTI… | $2.4M | $21.960 | Tablet |
| MYLAN PHARMACEUTICALS … | MYLAN LABORATORIES LTD | $228K | $0.216 | Tablet |
| NORTHSTAR DISTRIBUTION… | HETERO LABS LTD | $60K | $52.118 | Suspension |
| 60 DEGREES PHARMACEUTI… | PIRAMAL PHARMA LTD | $30K | $1.159 | Tablet |
Germany 3 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| CENTRAFARM SERVICES (A… | GLENMARK PHARMACEUTI… | $174K | $5.096 | Tablet |
| EUROGENERICS NVLIVLINA… | GLENMARK PHARMACEUTI… | $97K | $16.894 | Tablet |
| GLENMARK PHARMACEUTICA… | GLENMARK PHARMACEUTI… | $4K | $0.284 | Suspension |
Canada 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| GLENMARK PHARMACEUTICA… | GLENMARK PHARMACEUTI… | $134K | $55.848 | Tablet |
Mauritius 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| SCOTT HEALTH LTD | GLENMARK PHARMACEUTI… | $29K | $5.815 | Tablet |
Australia 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| PHARMACOR PTY LTD | ALKEM LABORATORIES LTD | $12K | $2.559 | Tablet |
§6.3 Price positioning — top 13 importers
| # | Importer | Country | USD | $/ship | Tier |
|---|---|---|---|---|---|
| 1 | GLENMARK PHARMACEUTI… | United States | $2.4M | $338K | Premium |
| 2 | MYLAN PHARMACEUTICAL… | United States | $228K | $46K | Premium |
| 3 | CENTRAFARM SERVICES … | Germany | $174K | $174K | Premium |
| 4 | GLENMARK PHARMACEUTI… | Canada | $134K | $134K | Premium |
| 5 | EUROGENERICS NVLIVLI… | Germany | $97K | $48K | Premium |
| 6 | NORTHSTAR DISTRIBUTI… | United States | $60K | $60K | Premium |
| 7 | 60 DEGREES PHARMACEU… | United States | $30K | $30K | Mid |
| 8 | SCOTT HEALTH LTD | Mauritius | $29K | $29K | Mid |
| 9 | PHARMACOR PTY LTD | Australia | $12K | $12K | Budget |
| 10 | ARTEMIS PHARMACEUTIC… | South Africa | $5K | $5K | Budget |
| 11 | GLENMARK PHARMACEUTI… | Germany | $4K | $1K | Budget |
| 12 | SMARK FZE | United Arab Emirates | $77.718 | $78.000 | Budget |
| 13 | STADA HEMOFARM SRL | Romania | $12.125 | $1.000 | Budget |
06
PART III — WHO’S IN THIS MARKET
Market Relationship Map
The top 8 × 13 supplier ↔ buyer network as a circular flow diagram
Fig 6.3 HETERO LABS LTD → GLENMARK PHARMACEUTICALS INC is the strongest relationship.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left semicircle = top 8 Indian suppliers; right = top 13 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian atovaquone prices vary by supplier, country and dosage form
KEY TAKEAWAY
Atovaquone prices span 14363× ($0.0046 → $66.24). The coefficient of variation is 0.95. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
§7.1 Price distribution · Table 7.1
| Statistic | Value | Interpretation |
|---|---|---|
| Min | $0.0046 | Lowest observed unit price |
| P5 | $0.043 | 5th percentile |
| P25 | $0.313 | 25th percentile (Q1) |
| Median | $14.18 | 50th percentile (Q2) |
| P75 | $64.31 | 75th percentile (Q3) |
| P95 | $66.24 | 95th percentile |
| Max | $66.24 | Highest observed unit price |
| Mean | $30.68 | Arithmetic average |
| CV | 95% | Coefficient of variation (std/mean) |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 7.1 HETERO LABS LTD prices at $63.50/unit vs market median $14.18.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. MYLAN LABORATORIES LTD Sourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. HETERO LABS LTD Sourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. Sourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. Sourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAY
Extreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Dec 2025 | HETERO LABS LTD | United States | Solution | 1K | $76K | $66.24 | Specialty / small-batch |
| Dec 2025 | HETERO LABS LTD | United States | Solution | 2K | $153K | $66.24 | Specialty / small-batch |
| Dec 2025 | HETERO LABS LTD | United States | Solution | 2K | $153K | $66.24 | Specialty / small-batch |
| Dec 2025 | HETERO LABS LTD | United States | Solution | 2K | $153K | $66.24 | Specialty / small-batch |
| Dec 2025 | HETERO LABS LTD | United States | Solution | 2K | $153K | $66.20 | Specialty / small-batch |
| Dec 2025 | HETERO LABS LTD | United States | Solution | 2K | $153K | $66.20 | Specialty / small-batch |
| Dec 2025 | HETERO LABS LTD | United States | Solution | 1K | $96K | $66.19 | Specialty / small-batch |
| Dec 2025 | HETERO LABS LTD | United States | Solution | 3K | $176K | $66.18 | Specialty / small-batch |
| Dec 2025 | HETERO LABS LTD | United States | Solution | 3K | $173K | $66.07 | Specialty / small-batch |
| Oct 2025 | HETERO LABS LTD | United States | Solution | 2K | $150K | $65.05 | Specialty / small-batch |
↓ TOP 10 LOWEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Dec 2025 | MYLAN LABORATORI… | United States | Tablet | 112K | $516.96 | $0.0046 | Bulk generic tablet |
| Dec 2025 | GLENMARK PHARMAC… | Romania | Tablet | 30 | $1.14 | $0.038 | Small sample / trial shipment |
| Dec 2025 | GLENMARK PHARMAC… | Romania | Tablet | 30 | $1.28 | $0.043 | Small sample / trial shipment |
| Dec 2025 | GLENMARK PHARMAC… | Romania | Tablet | 30 | $1.29 | $0.043 | Small sample / trial shipment |
| Dec 2025 | GLENMARK PHARMAC… | Romania | Tablet | 30 | $1.46 | $0.049 | Small sample / trial shipment |
| Dec 2025 | GLENMARK PHARMAC… | Romania | Tablet | 30 | $1.51 | $0.050 | Small sample / trial shipment |
| Dec 2025 | GLENMARK PHARMAC… | Romania | Tablet | 30 | $1.59 | $0.053 | Small sample / trial shipment |
| Dec 2025 | GLENMARK PHARMAC… | Romania | Tablet | 15 | $1.25 | $0.083 | Small sample / trial shipment |
| Dec 2025 | GLENMARK PHARMAC… | Romania | Tablet | 15 | $1.26 | $0.084 | Small sample / trial shipment |
| Dec 2025 | MYLAN LABORATORI… | United States | Tablet | 455K | $67K | $0.147 |
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
- Budget buyer: anchor − 10–15% (floor = cost + freight)
- Mid-market: anchor ± 5–10%
- Premium/tender: anchor + 10–25% (regulated, quality premium)
- Injection/infusion: always 4–10× the tablet price
KEY TAKEAWAYS
- Dosage form is the #1 price driver, not destination
- Light cells = easy-entry markets for small suppliers
- Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship atovaquone, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAY
Atovaquone leaves India through 6+ ports. The top 5 (HYDERABAD ICD, NHAVA SHEVA SEA (JNPT), MUMBAI AIR (SAHAR)) handle 99.9% of total USD. ICD moves 36% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 HYDERABAD ICD handles $3.1M — top 6 Indian origin ports by trade value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian port. Bar length = USD value. The largest ports handle the majority of trade.
Fig 8.2 New York is the #1 global destination port — top 18 by USD value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
| Route | Mode | Transit time | Notes |
|---|---|---|---|
| NHAVA SHEVA SEA (JNPT) → US East Coast | Sea | 22–28 days | Via Suez; 2–3 transshipments typical |
| NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria) | Sea | 18–24 days | Direct liner service available |
| MUMBAI AIR (SAHAR) → New York JFK | Air | 3–5 days | Direct cargo; cold-chain available |
| MUNDRA SEA → Rotterdam | Sea | 20–26 days | Via Suez; Hamburg also served |
| HYDERABAD AIR → London Heathrow | Air | 2–4 days | Pharma-grade cargo corridor |
| CHENNAI SEA → Chittagong (Bangladesh) | Sea | 7–12 days | Short-sea route; high frequency |
| RAXAUL → Birgunj (Nepal) | Road | 1–2 days | Land border crossing |
| NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya) | Sea | 14–20 days | Direct or via Colombo hub |
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAY
ICD dominates at 36% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
ICD
$3.1M
50.0% of USD · 36.4% of ships
SEA
$2.8M
45.4% of USD · 27.3% of ships
AIR
$291K
4.6% of USD · 36.4% of ships
Fig 8.3 The dominant corridor is HYDERABAD ICD → Sea → N. America ($3.1M).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAY
Romania is the most concentrated destination (HHI 10000, 1 suppliers). United States is the most competitive (HHI 4684).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 Romania (HHI 10,000) is the most concentrated — United States (HHI 4,684) is the most competitive.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 9 of 9 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
| Buyer | Country | Sole supplier | USD | Ships | Risk |
|---|---|---|---|---|---|
| GLENMARK PHARMACEUTI… | United States | GLENMARK PHARMAC… | $2.4M | 7 | CRITICAL |
| MYLAN PHARMACEUTICAL… | United States | MYLAN LABORATORI… | $228K | 5 | HIGH |
| CENTRAFARM SERVICES … | Germany | GLENMARK PHARMAC… | $174K | 1 | HIGH |
| GLENMARK PHARMACEUTI… | Canada | GLENMARK PHARMAC… | $134K | 1 | HIGH |
| EUROGENERICS NVLIVLI… | Germany | GLENMARK PHARMAC… | $97K | 2 | MEDIUM |
| NORTHSTAR DISTRIBUTI… | United States | HETERO LABS LTD | $60K | 1 | MEDIUM |
| 60 DEGREES PHARMACEU… | United States | PIRAMAL PHARMA LTD | $30K | 1 | MEDIUM |
| SCOTT HEALTH LTD | Mauritius | GLENMARK PHARMAC… | $29K | 1 | MEDIUM |
Conclusion: 13 buyers depend on exactly one Indian supplier, representing $3.1M in trade. 1 are rated CRITICAL — if their sole supplier fails, they have no backup. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
| Buyer | Country | Suppliers | USD | Dominant | Resilience |
|---|
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY
15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
| Country | Tier | Lead | Price | Risk | Entry approach |
|---|---|---|---|---|---|
| United States | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Germany | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Canada | Tier 3 (emerging) | 14–28 days (sea) | $1–$10/unit | LOW | First-mover advantage |
| Mauritius | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Australia | Tier 3 (emerging) | 14–28 days (sea) | $1–$10/unit | LOW | First-mover advantage |
| South Africa | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| American Samoa | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| United Arab Emirates | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Romania | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 9 in Fragile Dependency (concentrated + shrinking).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 9 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAY
Quick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 9 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A1 | Pitch top single-source buyer in United States | This Q | HIGH |
| A2 | Offer alternative to top multi-source buyer | This Q | HIGH |
| A3 | Audit Romania lock-ins (HHI 10000) | This Q | MED |
| A5 | Enter United States (4 suppliers) | This Q | HIGH |
| A6 | Enter Germany (1 suppliers) | This Q | MED |
| A8 | Build Germany distribution | 6–12m | HIGH |
| A9 | Bundle injection/infusion catalog for premium markets | 6–12m | MED |
B
FOR BUYERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A4 | Monitor rising exporters (climbers) | This Q | MED |
| A7 | Register for United States tenders | 6–12m | HIGH |
| A10 | Track quarterly HHI shifts across key destinations | This Q | LOW |
| A11 | Map competitor buyer portfolios quarterly | This Q | MED |
| A12 | Qualify second source for single-source buyers | This Q | MED |
§9.4 Easy-entry markets — 9 countries with ≤5 Indian suppliers
| # | Country | Region | Suppliers | Q4 USD | Growth | Barrier | Why this is easy |
|---|---|---|---|---|---|---|---|
| 1 | United States | Other | 4 | $5.8M | -45.5% | LOW | Low competition (4 suppliers), accessible market |
| 2 | Germany | Other | 1 | $275K | -98.4% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 3 | Canada | Other | 1 | $134K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 4 | Mauritius | Africa | 1 | $29K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 5 | Australia | Other | 1 | $12K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 6 | South Africa | Africa | 1 | $5K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 7 | American Samoa | Other | 1 | $1K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 8 | United Arab Emirates | Other | 1 | $78 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 9 | Romania | Other | 1 | $12 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
This report covers 55 2025-Q4 Atovaquone shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/atovaquone
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAY
This section contains every one of the 55 2025-Q4 atovaquone shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian atovaquone shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
55
across all regions
TOTAL USD
$6.27M
2025-Q4 FOB value
UNITS
1.3M
tablets, capsules, etc.
SUPPLIERS
8
Indian exporters
BUYERS
14
global importers
COUNTRIES
9
destinations
§10.2 Regional breakdown
§10.3 Key insights from the data
Africa is the largest region at $35K (0.6%), spanning 2 countries.
8 Indian suppliers shipped to 14 buyers across 9 countries — average shipment value $114K.
Top 0 markets: .
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
§10.4 How to read a country page
1
6 KPI cards — shipments, USD, qty, exporters, importers, avg unit price.
2
4 mini-lists — top exporters, importers, dosages, monthly trend.
3
Shipment register — every row grouped by exporter. No row is duplicated or omitted.
10
PART VI — DRILL-DOWN · AFRICA
Region: Africa
2 countries · 2 shipments · $35K · 2 Indian suppliers · 2 buyers
SHIPMENTS
2
USD
$35K
COUNTRIES
2
SUPPLIERS
2
BUYERS
2
HHI
7,390
concentrated
Top 2 destination countries in Africa
1
Mauritius (84.6%)
$29K
2
South Africa (15.4%)
$5K
Top 2 Indian suppliers into Africa
1
GLENMARK PHARMACEUTICALS LTD
$29K
2
HUMANIQE BIOPHARMACEUTICALS PVT LTD
$5K
Top 2 Africa importers
1
SCOTT HEALTH LTD · Mauritius
$29K
2
ARTEMIS PHARMACEUTICALS PTY LTD · South Africa
$5K
Top 1 dosage forms
1
Tablet
$35K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 0 | $0.0000 | — |
| Nov | 1 | $29K | $29K |
| Dec | 1 | $5K | $5K |
Shipment register · 2 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — GLENMARK PHARMACEUTICALS LTD · 1 shipments · $29K | |||||||||||
| 1 | Nov 2025 | SCOTT HEALTH LTD | Mauritius | Tablet | 5.0K | NOS | $5.82 | $29K | MUMBAI AIR (SAHAR) | MAURITIUS | AIR |
| SUPPLIER #2 — HUMANIQE BIOPHARMACEUTICALS PVT LTD · 1 shipments · $5K | |||||||||||
| 2 | Dec 2025 | ARTEMIS PHARMACEUTICALS PTY LTD | South Africa | Tablet | 440 | NOS | $12.16 | $5K | AHMEDABAD AIR | JOHANNESBURG - JOHAN | AIR |
10
PART VI — DRILL-DOWN · ASIA
Region: Asia
1 countries · 1 shipments · $77.72 · 1 Indian suppliers · 1 buyers
SHIPMENTS
1
USD
$77.72
COUNTRIES
1
SUPPLIERS
1
BUYERS
1
HHI
10,000
concentrated
Top 1 destination countries in Asia
1
United Arab Emirates (100.0%)
$77.72
Top 1 Indian suppliers into Asia
1
MEDLINE WORLD SURGICARE PVT LTD
$77.72
Top 1 Asia importers
1
SMARK FZE · United Arab Emirates
$77.72
Top 1 dosage forms
1
Tablet
$77.72
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 0 | $0.0000 | — |
| Nov | 1 | $77.72 | $77.72 |
| Dec | 0 | $0.0000 | — |
Shipment register · 1 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — MEDLINE WORLD SURGICARE PVT LTD · 1 shipments · $77.72 | |||||||||||
| 1 | Nov 2025 | SMARK FZE | United Arab Emirates | Tablet | 9 | PCS | $8.64 | $77.72 | DELHI AIR | DUBAI | AIR |
10
PART VI — DRILL-DOWN · EUROPE
Region: Europe
2 countries · 15 shipments · $275K · 1 Indian suppliers · 4 buyers
SHIPMENTS
15
USD
$275K
COUNTRIES
2
SUPPLIERS
1
BUYERS
4
HHI
10,000
concentrated
Top 2 destination countries in Europe
1
Germany (100.0%)
$275K
2
Romania (0.0%)
$12.12
Top 1 Indian suppliers into Europe
1
GLENMARK PHARMACEUTICALS LTD
$275K
Top 4 Europe importers
1
CENTRAFARM SERVICES (ALLOGA NL) B.V · Germany
$174K
2
EUROGENERICS NVLIVLINA GEENRODE · Germany
$97K
3
GLENMARK PHARMACEUTICALS S.R.O · Germany
$4K
4
STADA HEMOFARM SRL · Romania
$12.12
Top 2 dosage forms
1
Tablet
$270K
2
Suspension
$4K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 3 | $270K | $90K |
| Nov | 0 | $0.0000 | — |
| Dec | 12 | $4K | $357.89 |
Shipment register · 15 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — GLENMARK PHARMACEUTICALS LTD · 15 shipments · $275K | |||||||||||
| 1 | Oct 2025 | EUROGENERICS NVLIVLINA GEENRODE | Germany | Tablet | 2.8K | NOS | $11.17 | $32K | NHAVA SHEVA SEA (JNPT) | Hamburg | SEA |
| 2 | Oct 2025 | EUROGENERICS NVLIVLINA GEENRODE | Germany | Tablet | 2.9K | NOS | $22.46 | $65K | NHAVA SHEVA SEA (JNPT) | Hamburg | SEA |
| 3 | Oct 2025 | CENTRAFARM SERVICES (ALLOGA NL) B.V | Germany | Tablet | 34.1K | NOS | $5.10 | $174K | NHAVA SHEVA SEA (JNPT) | Hamburg | SEA |
| 4 | Dec 2025 | GLENMARK PHARMACEUTICALS S.R.O | Germany | Suspension | 7.7K | NOS | $0.313 | $2K | DELHI AIR | FRANKFURT/MAIN INT'L | AIR |
| 5 | Dec 2025 | GLENMARK PHARMACEUTICALS S.R.O | Germany | Suspension | 4.2K | NOS | $0.206 | $859.99 | DELHI AIR | FRANKFURT/MAIN INT'L | SEA |
| 6 | Dec 2025 | GLENMARK PHARMACEUTICALS S.R.O | Germany | Suspension | 3.3K | NOS | $0.312 | $1K | DELHI AIR | FRANKFURT/MAIN INT'L | AIR |
| 7 | Dec 2025 | STADA HEMOFARM SRL | Romania | Tablet | 30 | NOS | $0.049 | $1.46 | MUMBAI AIR (SAHAR) | BUCHAREST, OTOPENI | AIR |
| 8 | Dec 2025 | STADA HEMOFARM SRL | Romania | Tablet | 15 | NOS | $0.083 | $1.25 | MUMBAI AIR (SAHAR) | BUCHAREST, OTOPENI | AIR |
| 9 | Dec 2025 | STADA HEMOFARM SRL | Romania | Tablet | 8 | NOS | $0.168 | $1.34 | MUMBAI AIR (SAHAR) | BUCHAREST, OTOPENI | AIR |
| 10 | Dec 2025 | STADA HEMOFARM SRL | Romania | Tablet | 30 | NOS | $0.050 | $1.51 | MUMBAI AIR (SAHAR) | BUCHAREST, OTOPENI | AIR |
| 11 | Dec 2025 | STADA HEMOFARM SRL | Romania | Tablet | 15 | NOS | $0.084 | $1.26 | MUMBAI AIR (SAHAR) | BUCHAREST, OTOPENI | AIR |
| 12 | Dec 2025 | STADA HEMOFARM SRL | Romania | Tablet | 30 | NOS | $0.043 | $1.29 | MUMBAI AIR (SAHAR) | BUCHAREST, OTOPENI | AIR |
| 13 | Dec 2025 | STADA HEMOFARM SRL | Romania | Tablet | 30 | NOS | $0.043 | $1.28 | MUMBAI AIR (SAHAR) | BUCHAREST, OTOPENI | AIR |
| 14 | Dec 2025 | STADA HEMOFARM SRL | Romania | Tablet | 30 | NOS | $0.038 | $1.14 | MUMBAI AIR (SAHAR) | BUCHAREST, OTOPENI | AIR |
| 15 | Dec 2025 | STADA HEMOFARM SRL | Romania | Tablet | 30 | NOS | $0.053 | $1.59 | MUMBAI AIR (SAHAR) | BUCHAREST, OTOPENI | SEA |
10
PART VI — DRILL-DOWN · AMERICAS
Region: Americas
3 countries · 36 shipments · $5.95M · 5 Indian suppliers · 6 buyers
SHIPMENTS
36
USD
$5.95M
COUNTRIES
3
SUPPLIERS
5
BUYERS
6
HHI
4,657
concentrated
Top 3 destination countries in Americas
1
United States (97.7%)
$5.81M
2
Canada (2.3%)
$134K
3
American Samoa (0.0%)
$1K
Top 5 Indian suppliers into Americas
1
HETERO LABS LTD
$3.19M
2
GLENMARK PHARMACEUTICALS LTD
$2.50M
3
MYLAN LABORATORIES LTD
$228K
4
PIRAMAL PHARMA LTD
$30K
5
VIVALDIS HEALTH AND FOODS PVT LTD
$1K
Top 5 Americas importers
1
GLENMARK PHARMACEUTICALS INC · United States
$2.36M
2
MYLAN PHARMACEUTICALS INC · United States
$228K
3
GLENMARK PHARMACEUTICALS CANADA INC · Canada
$134K
4
NORTHSTAR DISTRIBUTION CENTER · United States
$60K
5
60 DEGREES PHARMACEUTICALS · United States
$30K
Top 3 dosage forms
1
Tablet
$2.76M
2
Solution
$2.74M
3
Suspension
$454K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 16 | $3.53M | $220K |
| Nov | 3 | $573K | $191K |
| Dec | 17 | $1.85M | $109K |
Shipment register · 36 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — HETERO LABS LTD · 21 shipments · $3.19M | |||||||||||
| 1 | Oct 2025 | UNLISTED BUYER | United States | Solution | 2.3K | NOS | $65.05 | $150K | HYDERABAD ICD | NEW YORK | ICD |
| 2 | Oct 2025 | UNLISTED BUYER | United States | Solution | 2.6K | NOS | $65.03 | $168K | HYDERABAD ICD | NEW YORK | ICD |
| 3 | Oct 2025 | NORTHSTAR DISTRIBUTION CENTER | United States | Suspension | 1.2K | NOS | $52.12 | $60K | HYDERABAD AIR | CHICAGO O'HARE INT'L | AIR |
| 4 | Oct 2025 | UNLISTED BUYER | United States | Suspension | 3.8K | NOS | $52.12 | $197K | HYDERABAD ICD | SAVANNAH | ICD |
| 5 | Oct 2025 | UNLISTED BUYER | United States | Suspension | 3.8K | NOS | $52.12 | $197K | HYDERABAD ICD | Savannah | ICD |
| 6 | Oct 2025 | UNLISTED BUYER | United States | Solution | 2.6K | NOS | $64.28 | $170K | HYDERABAD ICD | NEW YORK | ICD |
| 7 | Oct 2025 | UNLISTED BUYER | United States | Solution | 2.3K | NOS | $64.30 | $148K | HYDERABAD ICD | NEW YORK | ICD |
| 8 | Oct 2025 | UNLISTED BUYER | United States | Solution | 2.7K | NOS | $64.29 | $171K | HYDERABAD ICD | New York | ICD |
| 9 | Oct 2025 | UNLISTED BUYER | United States | Solution | 2.6K | NOS | $64.29 | $165K | HYDERABAD ICD | New York | ICD |
| 10 | Oct 2025 | UNLISTED BUYER | United States | Solution | 2.3K | NOS | $64.31 | $148K | HYDERABAD ICD | New York | ICD |
| 11 | Dec 2025 | UNLISTED BUYER | United States | Solution | 2.6K | NOS | $64.88 | $168K | HYDERABAD ICD | NEW YORK | ICD |
| 12 | Dec 2025 | UNLISTED BUYER | United States | Solution | 2.6K | NOS | $64.88 | $168K | HYDERABAD ICD | NEW YORK | ICD |
| 13 | Dec 2025 | UNLISTED BUYER | United States | Solution | 1.5K | NOS | $66.19 | $96K | HYDERABAD ICD | NEW YORK | ICD |
| 14 | Dec 2025 | UNLISTED BUYER | United States | Solution | 2.3K | NOS | $66.24 | $153K | HYDERABAD ICD | NEW YORK | ICD |
| 15 | Dec 2025 | UNLISTED BUYER | United States | Solution | 2.3K | NOS | $66.24 | $153K | HYDERABAD ICD | NEW YORK | ICD |
| 16 | Dec 2025 | UNLISTED BUYER | United States | Solution | 2.6K | NOS | $66.07 | $173K | HYDERABAD ICD | NEW YORK | ICD |
| 17 | Dec 2025 | UNLISTED BUYER | United States | Solution | 2.3K | NOS | $66.24 | $153K | HYDERABAD ICD | NEW YORK | ICD |
| 18 | Dec 2025 | UNLISTED BUYER | United States | Solution | 1.2K | NOS | $66.24 | $76K | HYDERABAD ICD | NEW YORK | ICD |
| 19 | Dec 2025 | UNLISTED BUYER | United States | Solution | 2.7K | NOS | $66.18 | $176K | HYDERABAD ICD | NEW YORK | ICD |
| 20 | Dec 2025 | UNLISTED BUYER | United States | Solution | 2.3K | NOS | $66.20 | $153K | HYDERABAD ICD | NEW YORK | ICD |
| 21 | Dec 2025 | UNLISTED BUYER | United States | Solution | 2.3K | NOS | $66.20 | $153K | HYDERABAD ICD | NEW YORK | ICD |
| SUPPLIER #2 — GLENMARK PHARMACEUTICALS LTD · 8 shipments · $2.50M | |||||||||||
| 22 | Oct 2025 | GLENMARK PHARMACEUTICALS CANADA INC | Canada | Tablet | 2.4K | NOS | $55.85 | $134K | NHAVA SHEVA SEA (JNPT) | Montreal | SEA |
| 23 | Oct 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 28.8K | NOS | $10.61 | $305K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 24 | Oct 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 8.3K | NOS | $46.20 | $384K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 25 | Oct 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 8.3K | NOS | $46.24 | $384K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 26 | Oct 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 8.3K | NOS | $46.24 | $384K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 27 | Oct 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 34.7K | NOS | $10.48 | $363K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 28 | Nov 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 8.3K | NOS | $46.68 | $388K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 29 | Nov 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 10.9K | NOS | $14.18 | $155K | NHAVA SHEVA SEA (JNPT) | Newark Apt/New York | SEA |
| SUPPLIER #3 — MYLAN LABORATORIES LTD · 5 shipments · $228K | |||||||||||
| 30 | Dec 2025 | MYLAN PHARMACEUTICALS INC | United States | Tablet | 224.0K | NOS | $0.413 | $93K | MUMBAI AIR (SAHAR) | ATLANTA, HARTSFIELD | AIR |
| 31 | Dec 2025 | MYLAN PHARMACEUTICALS INC | United States | Tablet | 112.1K | NOS | $0.0046 | $516.96 | MUMBAI AIR (SAHAR) | ATLANTA, HARTSFIELD | AIR |
| 32 | Dec 2025 | MYLAN PHARMACEUTICALS INC | United States | Tablet | 110.1K | NOS | $0.413 | $45K | MUMBAI AIR (SAHAR) | ATLANTA, HARTSFIELD | AIR |
| 33 | Dec 2025 | MYLAN PHARMACEUTICALS INC | United States | Tablet | 153.6K | NOS | $0.147 | $23K | MUMBAI AIR (SAHAR) | ATLANTA, HARTSFIELD | AIR |
| 34 | Dec 2025 | MYLAN PHARMACEUTICALS INC | United States | Tablet | 454.7K | NOS | $0.147 | $67K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| SUPPLIER #4 — PIRAMAL PHARMA LTD · 1 shipments · $30K | |||||||||||
| 35 | Nov 2025 | 60 DEGREES PHARMACEUTICALS | United States | Tablet | 26.2K | NOS | $1.16 | $30K | MUMBAI AIR (SAHAR) | PHILADELPHIA METROP | AIR |
| SUPPLIER #5 — VIVALDIS HEALTH AND FOODS PVT LTD · 1 shipments · $1K | |||||||||||
| 36 | Dec 2025 | UNLISTED BUYER | American Samoa | Tablet | 200 | NOS | $5.59 | $1K | MUMBAI AIR (SAHAR) | BANDAR SERI B | AIR |
10
PART VI — DRILL-DOWN · OCEANIA
Region: Oceania
1 countries · 1 shipments · $12K · 1 Indian suppliers · 1 buyers
SHIPMENTS
1
USD
$12K
COUNTRIES
1
SUPPLIERS
1
BUYERS
1
HHI
10,000
concentrated
Top 1 destination countries in Oceania
1
Australia (100.0%)
$12K
Top 1 Indian suppliers into Oceania
1
ALKEM LABORATORIES LTD
$12K
Top 1 Oceania importers
1
PHARMACOR PTY LTD · Australia
$12K
Top 1 dosage forms
1
Tablet
$12K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 1 | $12K | $12K |
| Nov | 0 | $0.0000 | — |
| Dec | 0 | $0.0000 | — |
Shipment register · 1 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — ALKEM LABORATORIES LTD · 1 shipments · $12K | |||||||||||
| 1 | Oct 2025 | PHARMACOR PTY LTD | Australia | Tablet | 4.8K | NOS | $2.56 | $12K | NHAVA SHEVA SEA (JNPT) | Sydney | SEA |
10
PART VI — EVIDENCE REGISTER
Indian Supplier Directory
All 8 Indian atovaquone exporters — complete list ranked by USD
KEY TAKEAWAY
This directory lists every Indian company that shipped atovaquone in 2025-Q4.
S FOR SUPPLIERS
Find yourself and your competitors. Compare shipment count, USD, and destination regions.
B FOR BUYERS
Search for potential Indian suppliers. Filter by dosage form and destination region.
| # | Supplier | City | Ships | USD | Dosage forms | Primary regions |
|---|---|---|---|---|---|---|
| 1 | HETERO LABS LTD | HYDERABAD | 21 | $3.19M | Solution, Suspension | Americas |
| 2 | GLENMARK PHARMACEUTICALS LTD | MUMBAI. MAHARASHTRA | 24 | $2.80M | Tablet, Suspension | Europe, Americas |
| 3 | MYLAN LABORATORIES LTD | NASHIK | 5 | $228K | Tablet | Americas |
| 4 | PIRAMAL PHARMA LTD | DHAR | 1 | $30K | Tablet | Americas |
| 5 | ALKEM LABORATORIES LTD | MUMBAI | 1 | $12K | Tablet | Oceania |
| 6 | HUMANIQE BIOPHARMACEUTICALS PVT LTD | VISHAKHAPATNAM | 1 | $5K | Tablet | Africa |
| 7 | VIVALDIS HEALTH AND FOODS PVT LTD | PUNE | 1 | $1K | Tablet | Americas |
| 8 | MEDLINE WORLD SURGICARE PVT LTD | DELHI | 1 | $77.72 | Tablet | Asia |
10
PART VI — EVIDENCE REGISTER
Global Buyer Directory
All 13 global atovaquone importers — complete list ranked by USD
KEY TAKEAWAY
This directory lists every company that imported Indian atovaquone in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
| # | Buyer | Country | Ships | USD | Primary supplier | Dosage forms |
|---|---|---|---|---|---|---|
| 1 | GLENMARK PHARMACEUTICALS INC | United States | 7 | $2.36M | GLENMARK PHARMACEUTI… | Tablet |
| 2 | MYLAN PHARMACEUTICALS INC | United States | 5 | $228K | MYLAN LABORATORIES LTD | Tablet |
| 3 | CENTRAFARM SERVICES (ALLOGA NL) B.V | Germany | 1 | $174K | GLENMARK PHARMACEUTI… | Tablet |
| 4 | GLENMARK PHARMACEUTICALS CANADA INC | Canada | 1 | $134K | GLENMARK PHARMACEUTI… | Tablet |
| 5 | EUROGENERICS NVLIVLINA GEENRODE | Germany | 2 | $97K | GLENMARK PHARMACEUTI… | Tablet |
| 6 | NORTHSTAR DISTRIBUTION CENTER | United States | 1 | $60K | HETERO LABS LTD | Suspension |
| 7 | 60 DEGREES PHARMACEUTICALS | United States | 1 | $30K | PIRAMAL PHARMA LTD | Tablet |
| 8 | SCOTT HEALTH LTD | Mauritius | 1 | $29K | GLENMARK PHARMACEUTI… | Tablet |
| 9 | PHARMACOR PTY LTD | Australia | 1 | $12K | ALKEM LABORATORIES LTD | Tablet |
| 10 | ARTEMIS PHARMACEUTICALS PTY LTD | South Africa | 1 | $5K | HUMANIQE BIOPHARMACE… | Tablet |
| 11 | GLENMARK PHARMACEUTICALS S.R.O | Germany | 3 | $4K | GLENMARK PHARMACEUTI… | Suspension |
| 12 | SMARK FZE | United Arab Emirates | 1 | $77.72 | MEDLINE WORLD SURGIC… | Tablet |
| 13 | STADA HEMOFARM SRL | Romania | 9 | $12.12 | GLENMARK PHARMACEUTI… | Tablet |
This report covers 55 2025-Q4 Atovaquone shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/atovaquone
Talk to our trade analyst
Need a custom atovaquone report or a deeper dive into any market? Our team is ready.
WhatsApp: +91 95950 78788 · transdatanexus.com
PHARMA TRADE INTELLIGENCE
Thank you for reading
This report is part of the TransData Nexus Pharma Trade Intelligence series, covering 366 pharmaceutical products exported from India.
Every figure is grounded in real commercial trade records — official customs filings and licensed databases. No surveys, no estimates, no fake data.
Need a custom report?
We can generate intelligence for any pharmaceutical product, any time period, any combination of source and destination countries.
Want deeper analysis?
Our team provides competitive intelligence, market entry strategy, and supply chain due diligence for pharma importers and exporters.
Scan for product page
WhatsApp: +91 95950 78788
Email: info@transdatanexus.com
Web: https://transdatanexus.com/pharmaceutical/atovaquone
© 2026 TransData Nexus. All rights reserved. This report is provided for informational purposes only.
Data sourced from official customs filings and licensed commercial trade databases.
Reproduction without permission is prohibited.
Explore the full Atovaquone product page
Live data, supplier directory, price trends, and trade route analysis